Avalo Q2 2026 Earnings: $472.2 Million Supports 2027 Clinical Milestones

Avalo Therapeutics (NASDAQ: AVTX) reported a second-quarter 2026 net loss of $36.4 million, or $0.83 per diluted share, compared with a $20.8 million loss, or $1.92 per share, in Q2 2025. Losses widened as research and administrative spending increased, but the per-share loss narrowed because weighted average shares rose to 43.6 million from 10.8 million. Cash, cash equivalents and investments totaled $472.2 million at June 30, 2026, which Avalo expects to fund operations into 2029.

Core financial results

Research and development expense increased by $9.3 million, primarily because Avalo recognized a $10.0 million development milestone for abdakibart and incurred additional costs supporting its development in hidradenitis suppurativa. General and administrative expense rose by $2.9 million, mainly because of higher stock-based compensation.

The larger net loss also reflected $4.8 million of net other expense, compared with $1.4 million a year earlier. The latest quarter included a $6.6 million change in the fair value of contingent consideration and a $1.0 million change in the fair value of a derivative liability, partly offset by $2.8 million of net interest income.

Pipeline and clinical milestones

Avalo said it delivered positive topline results from the Phase 2 LOTUS study of abdakibart in hidradenitis suppurativa, although the earnings release did not provide detailed efficacy or safety data. The company now plans to move the candidate into a registrational Phase 3 program.

Avalo also expanded its pipeline with AVTX-010, an Fc-engineered, long-acting anti-IL-1β antibody designed to extend half-life while preserving abdakibart’s pharmacology and specificity. Both disclosed 2027 milestones are scheduled for the first half of the year.

Cash flow and balance sheet

Avalo held $85.4 million in cash and cash equivalents, $314.9 million in short-term investments and $71.9 million in long-term investments at June 30. Together, these totaled the reported $472.2 million liquidity position, compared with approximately $98.3 million in cash and investments at December 31, 2025.

Net cash used in operating activities was $37.7 million for the six months ended June 30, 2026; this is a year-to-date figure rather than quarterly cash use. Management expects the current cash and investment balance to provide an operating runway into 2029, covering the planned 2027 clinical and regulatory milestones under its present assumptions.

The larger liquidity position came alongside a substantial increase in common shares outstanding, which reached 52.9 million at June 30 from 18.5 million at the end of 2025. Additional paid-in capital increased to $953.7 million from $531.5 million over the same period.

A wider net loss but a narrower per-share loss

Avalo’s total net loss widened by approximately 75%, while its diluted loss per share declined from $1.92 to $0.83. This divergence did not reflect an improvement in operating profitability: weighted average common shares increased about fourfold to 43.6 million, spreading the loss across a much larger share base.

The same effect is visible in the period-end share count. Investors therefore need to distinguish between the company’s larger absolute loss and the mechanically lower loss reported for each share.

Recent insider transactions

The supplied six-month aggregate reported 24 purchases covering 636,823 shares and 15 sales covering 325,868 shares, resulting in net purchases of 310,955 shares. Total insider holdings were listed as 903.08 thousand shares, with a reported net-purchase percentage of 52.50%.

The latest ten supplied records were all direct transactions. They mainly consisted of exercise or conversion transactions and sales by officer Mittie Doyle, followed by two zero-price stock awards.

These records describe the transactions but do not, by themselves, establish the insiders’ views of Avalo’s prospects.

Risks investors need to watch

• Clinical and regulatory execution: Avalo still needs to begin abdakibart’s registrational Phase 3 program and submit AVTX-010’s IND. Prior clinical results do not ensure future trial or regulatory outcomes.
• Rising development spending: R&D expense increased to $23.4 million as the company recognized an abdakibart milestone and supported further development. Advancing into Phase 3 could keep development costs material.
• Cash-runway assumptions: The expected runway into 2029 is based on management’s current plans and spending assumptions. Changes in trial timing, scope or costs could alter that estimate.
• Share dilution: The sharp increase in weighted average and period-end shares reduced the per-share loss even as the absolute net loss widened.
• Fair-value-related earnings volatility: Changes in contingent consideration and derivative liabilities added $7.6 million of expense in Q2 and may continue to affect reported results independently of clinical progress.

Conclusion

Avalo’s Q2 2026 results reflected a company funding its transition toward later-stage development: liquidity increased substantially, while R&D spending and the absolute net loss also rose. The main operating checkpoints are the planned abdakibart Phase 3 launch and AVTX-010 IND submission in the first half of 2027, while investors should monitor development spending, dilution and whether the projected cash runway remains intact.